MOVANTIK is taken once a day in the morning, on an empty stomach,* for the duration of opioid treatment.1
In the same 2 studies, response rate for MOVANTIK was 40% to 44% with a 25 mg dose and 35% to 41% with a 12.5 mg dose.1
Study Design: A total of 652 patients in KODIAC-04 and 700 patients in KODIAC-05, aged 18 to 84 years (mean age 52 years), with chronic non-cancer pain and opioid-induced constipation, were randomized to take MOVANTIK 12.5 mg, MOVANTIK 25 mg, or placebo once daily for 12 weeks. The patients who participated in KODIAC-04 and KODIAC-05 were taking a wide range of opioids. Before study enrollment, patients had been using their current opioid for an average of 3.6 and 3.7 years. Primary endpoint was response rate, defined as ≥3 spontaneous bowel movements per week (without use of rescue laxative in the previous 24 hours) and ≥1 spontaneous bowel movement per week over baseline.1,2
*At least 1 hour prior to the first meal of the day or 2 hours after the meal. Consumption of grapefruit or grapefruit juice during treatment with MOVANTIK is to be avoided.1
MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.
You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RedHill Biopharma Inc. supports the responsible use of medications, including those containing opioids, as treatment options for patients with chronic non-cancer pain.
This site is intended for US Consumers only.
The information on this website should not take the place of talking with your doctor or health care professional. If you have any questions about your condition, or if you would like more information about MOVANTIK, or about constipation caused by opioid use for chronic non-cancer pain, talk to your doctor or pharmacist. Only you and your doctor can decide if MOVANTIK is right for you.
RedHill Biopharma Inc. (U.S. Office)
8041 Arco Corporate Drive, Suite 200
Raleigh, NC 27617